Adding Umifenovir Doesn't Enhance Efficacy Of Favipiravir Drug Regimen

Adding antiviral Umifenovir in Favipiravir drug regimen does not enhance the effectiveness of the latter, asserted Glenmark Pharmaceuticals on October 9. Reportedly, the pharmaceutical company had conducted clinical trials to determine the efficacy of addition of Umifenovir against mono-therapy of Favipiravir tablets. Earlier, Glenmark had conducted clinical trials to determine the use of Favipiravir for COVID-19 treatment and had eventually obtained 'Emergency Use Authorisation' for the same.